Phase 2/3 biomarker-driven master protocol for previously treated squamous cell lung cancer (LUNG-MAP)

This treatment trial, which is part of the LUNG-MAP larger clinical study, is for patients who have been diagnosed with certain types of squamous cell lung cancer. Participants will receive two medications intravenously:

• Durvalumab, an FDA-approved immunotherapy for cancer
• Tremelimumab, a human monoclonal antibody that is known as an immune checkpoint blocker

Patients will undergo intravenous infusion of both drugs on day 1 for 4 courses, and then tremelimumab alone on day 1 of course 5 and subsequent courses unless disease progresses or toxicity occurs. Courses repeat every 28 days.

Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4, and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.